Does TARLATAMAB-DLLE Cause Unevaluable event? 5 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 5 reports of Unevaluable event have been filed in association with TARLATAMAB-DLLE (IMDELLTRA (AMG757)). This represents 0.6% of all adverse event reports for TARLATAMAB-DLLE.
5
Reports of Unevaluable event with TARLATAMAB-DLLE
0.6%
of all TARLATAMAB-DLLE reports
0
Deaths
5
Hospitalizations
How Dangerous Is Unevaluable event From TARLATAMAB-DLLE?
Of the 5 reports, 5 (100.0%) required hospitalization, and 1 (20.0%) were considered life-threatening.
Is Unevaluable event Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TARLATAMAB-DLLE. However, 5 reports have been filed with the FAERS database.
What Other Side Effects Does TARLATAMAB-DLLE Cause?
Cytokine release syndrome (274)
Immune effector cell-associated neurotoxicity syndrome (127)
Off label use (111)
Pyrexia (75)
Small cell lung cancer (66)
Death (45)
Disease progression (34)
Metastases to central nervous system (28)
Decreased appetite (23)
Dysgeusia (22)
What Other Drugs Cause Unevaluable event?
ADALIMUMAB (4,242)
ETANERCEPT (3,902)
LENALIDOMIDE (3,331)
OXYCODONE (3,145)
AMBRISENTAN (2,336)
SODIUM OXYBATE (2,328)
CARBIDOPA\LEVODOPA (1,632)
DUPILUMAB (1,410)
MORPHINE (1,161)
ACETAMINOPHEN\HYDROCODONE (1,118)
Which TARLATAMAB-DLLE Alternatives Have Lower Unevaluable event Risk?
TARLATAMAB-DLLE vs TASIGNA
TARLATAMAB-DLLE vs TASIMELTEON
TARLATAMAB-DLLE vs TAVABOROLE
TARLATAMAB-DLLE vs TAXOL
TARLATAMAB-DLLE vs TAXOTERE